Lupin and Zydus Lifesciences have signed a licensing and supply agreement for co-marketing Saroglitazar Mg to treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in India.

Saroglitazar Mg, taken once daily at a 4mg dose, enhances patient compliance and lowers the number of pills required.

In 2013, the drug was introduced in the country to treat diabetic dyslipidemia and hypertriglyceridemia in patients with type 2 diabetes (T2D) not controlled by statins alone.

In January 2020, Saroglitazar Mg received approval to treat patients with T2D mellitus. In March of the same year, it received approval to treat NASH.

Lupin will own semi-exclusive rights for co-marketing the drug in India under the LINVAS brand name.

Zydus introduced the drug with the brand names Bilypsa and Lipaglyn and will continue their marketing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based on the achievement of pre-defined milestones, Zydus will receive upfront licensing fees and milestone payments from Lupin.

Lupin managing director Nilesh Gupta stated: “We are excited to partner with Zydus to market Saroglitazar Mg for the treatment of NAFLD/NASH.

“This partnership re-affirms our commitment to grow and expand our offerings to meet unmet needs of patients in India.

“This partnership will further enhance our gastroenterology portfolio, offering better access to healthcare options to our patients and medical professionals.”

NAFLD is not limited to obese individuals or those with diabetes mellitus in India. It has also been observed that NAFLD can develop in non-obese individuals, and is referred to as “lean” NAFLD.